Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Jan 12;23(1):14–18. doi: 10.1002/jcla.20276

Prognostic value of combination of heart‐type fatty acid‐binding protein and ischemia‐modified albumin in patients with acute coronary syndromes and normal troponin T values

Cui Liyan 1, Zhang Jie 1,✉, Hu Xiaozhou 1
PMCID: PMC6649023  PMID: 19140206

Abstract

Recent studies have suggested that heart‐type fatty acid‐binding protein (H‐FABP) may detect ongoing myocardial damage involved in the progression of acute coronary syndromes (ACS). This study was prospectively designed to examine whether the combination of H‐FABP, a marker for ongoing myocardial damage, and ischemia‐modified albumin (IMA), a marker for myocardial ischemia, would effectively diagnose patients with ACS. H‐FABP values above 1.5 µg/l can be correctly measured via an ELISA and 6 µg/l is the currently used cut‐off value (1–3). We measured serum H‐FABP and IMA of 108 patients on admission within 12 hr after onset of chestpain and normal troponin T. serum samplesfrom ACS group (n=82) had decreased capacity of ACB [64 (61–67) U/ml] compared with non‐ACS ischemic chest pain group (n=26) samples [75 (71–78) U/ml] (P<0.05). The combination of IMA and H‐FABP usually had better sensitivity [96.3% (92.2–100%)] (P<0.05) and accuracy [92.6 (87.7–97.5%)] (P<0.05) than when individually used. Thus, the combination of H‐FABP and IMA measurements after initiation of chest pain may be highly effective for risk stratification in patients with ACS and normal cardiac troponin T. J. Clin. Lab. Anal. 23:14–18, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: acute coronary syndrome, myocardial ischemia, fatty acid‐binding proteins, biomarkers

REFERENCES

  • 1. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959–969. [DOI] [PubMed] [Google Scholar]
  • 2. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST–segment elevation. Eur Heart J 2002;23:1809–1840. [DOI] [PubMed] [Google Scholar]
  • 3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non—ST‐segment elevation myocardial infarction. A report of the American Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970–1062. [DOI] [PubMed] [Google Scholar]
  • 4. Hamm CW. Acute coronary syndromes: The diagnostic role of troponins. Tromb Res 2001;103:S63–S69. [DOI] [PubMed] [Google Scholar]
  • 5. Chan CP, Wan TS, Watkins KL, et al. Rapid analysis of fatty acid‐binding proteins with immunosensors and immunotests for early monitoring of tissue injury. Biosens Bioelectron 2005; 20:2566–2580. [DOI] [PubMed] [Google Scholar]
  • 6. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: The potential value of heart fatty‐acid‐binding protein. Q J Med 2004;97:187–198. [DOI] [PubMed] [Google Scholar]
  • 7. Pelsers MM, Hermens WT, Glatz JF. Fatty acid‐binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005;352:15–35. [DOI] [PubMed] [Google Scholar]
  • 8. Pagani F, Bonora R, Bonetti G. Evaluation of a sandwich enzyme‐linked immunosorbent assay for the measurement of serum heart fatty acid‐binding protein. Ann Clin Biochem 2002;39:404–405. [DOI] [PubMed] [Google Scholar]
  • 9. Glatz JF, van der Vusse GJ. Cellular fatty acid‐binding proteins: Their function and physiological significance. Prog Lipid Res 1996;35:243–282. [DOI] [PubMed] [Google Scholar]
  • 10. Storch J, Thumser AE. The fatty acid transport function of fatty acid‐binding proteins. Biochim Biophys Acta 2000;1486:28–44. [DOI] [PubMed] [Google Scholar]
  • 11. Schaap FG, Binas B, Danneberg H, van der Vusse GJ, Glatz JF. Impaired long‐chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart‐type fatty acid binding protein gene. Circ Res 1999;85:329–337. [DOI] [PubMed] [Google Scholar]
  • 12. Fournier NC, Richard MA. Role of fatty acid‐binding protein in cardiac fatty acid oxidation. Mol Cell Biochem 1990;98:149–159. [DOI] [PubMed] [Google Scholar]
  • 13. Pelsers MM, et al. Influence of age, sex and day‐to‐day and within‐day biological variations on plasma concentrations of fatty acid‐binding protein and myoglobin in healthy subjects. Clin Chem 1999;45:441–443. [PubMed] [Google Scholar]
  • 14. Bruins Slot MH, van der Heijden GJ, Rutten FH, et al. Heart‐type fatty acid‐binding protein in acute myocardial infarction evaluation (FAME): background and design of a diagnostic study in primary care. BMC Cardiovasc Disord 2008;8:8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Figiel L, Kasprzak JD, Peruga J, et al. Heart‐type fatty acid binding protein—a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation. Kardiol Pol 2008;66:253–259. [PubMed] [Google Scholar]
  • 16. Mad P, Domanovits H, Fazelnia C, et al. Human heart‐type fatty‐acid‐binding protein as a point‐of‐care test in the early diagnosis of acute myocardial infarction. QJM 2007;100:203–210. [DOI] [PubMed] [Google Scholar]
  • 17. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart‐type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550–557. [DOI] [PubMed] [Google Scholar]
  • 18. Nahahara D, Nakata T, Hashimoto A, et al. Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Circ J 2006;70:419–425. [DOI] [PubMed] [Google Scholar]
  • 19. Suzuki M, Hori S, Noma S, et al. Prognostic value of a qualitative test for heart‐type fatty acid‐binding protein in patients with acute coronary syndrome. Int Heart J 2005;46:601–606. [DOI] [PubMed] [Google Scholar]
  • 20. Liyan C, Jie Z, Yonghua W, et al. Assay of ischemia‐modified albumin and C‐reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008;22:45–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Erlikh A, Katrukha AG, Trifonov IR, et al. Prognostic significance of heart fatty acid‐binding protein in patients with non‐ST elevation acute coronary syndrome: results of follow‐up for twelve months. Kardiologiia 2005;45:13–21. [PubMed] [Google Scholar]
  • 22. Christenson RL, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47:464–470. [PubMed] [Google Scholar]
  • 23. Sinha MK, Roy D, Gaze DC, et al. Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C‐reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–424. [DOI] [PubMed] [Google Scholar]
  • 25. Tanaka T, Hirota Y, Sohmiya K, et al. Serum and urinary human heart fatty acid‐binding protein in acute myocardial infarction. Clin Biochem 1991;24:195–201. [DOI] [PubMed] [Google Scholar]
  • 26. Kleine AH, Glatz JF, Van Nieuwenhoven FA, et al. Release of heart fatty acid‐binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992;116:155–162. [DOI] [PubMed] [Google Scholar]
  • 27. Nakata T, Hashimoto A, Hase M, et al. Human heart‐type fatty acid‐binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology 2003;99:96–104. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES